Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on TG Therapeutics (TGTX – Research Report). The associated price target remains the same with $55.00.
Edward White has given his Buy rating due to a combination of factors including the promising data presentations for Briumvi at the American Academy of Neurology 2025 annual meeting. Briumvi, a novel treatment for relapsing forms of multiple sclerosis, demonstrated a favorable tolerability profile in real-world settings, with a lower incidence of infusion-related reactions compared to previous trials. The company is also planning a Phase 4 study to further evaluate Briumvi’s effectiveness and safety, which adds to the confidence in its market potential.
Additionally, TG Therapeutics has projected significant revenue growth for Briumvi, with U.S. net product revenue expected to reach $115 million in the first quarter of 2025 and a global revenue target of approximately $540 million for the full year. The analyst’s price target of $55 is based on the net present value of revenue forecasts through 2028, using a price-to-sales multiple that aligns with industry peers. This financial outlook, combined with the positive clinical data, supports the Buy rating for TG Therapeutics.